Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000644602 | SCV000766302 | likely benign | Congenital myasthenic syndrome 5 | 2024-12-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002528910 | SCV003750275 | uncertain significance | Inborn genetic diseases | 2021-09-09 | criteria provided, single submitter | clinical testing | The c.167C>T (p.P56L) alteration is located in exon 2 (coding exon 2) of the COLQ gene. This alteration results from a C to T substitution at nucleotide position 167, causing the proline (P) at amino acid position 56 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000644602 | SCV003828308 | uncertain significance | Congenital myasthenic syndrome 5 | 2019-05-28 | criteria provided, single submitter | clinical testing |